Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism - Wikidata - awgldk - TriplyDB

Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism

Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism

http://www.wikidata.org/entity/Q35169945

about

Diabetic complications within the context of aging: Nicotinamide adenine dinucleotide redox, insulin C-peptide, sirtuin 1-liver kinase B1-adenosine monophosphate-activated protein kinase positive feedback and forkhead box O3 Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.Improved Insulin Sensitivity 3 Months After RYGB Surgery Is Associated With Increased Subcutaneous Adipose Tissue AMPK Activity and Decreased Oxidative Stress.Activation of AMP-Activated Protein Kinase by Adenine Alleviates TNF-Alpha-Induced Inflammation in Human Umbilical Vein Endothelial Cells.The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1a/JNK/caspase-3 pathway.AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System.Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway.Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.Effect of liraglutide on dietary lipid-induced insulin resistance in humans.Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness.Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.

P2860

Q26749486-079A1506-0DE5-451E-9FB6-BFB1A95A1196 Q26750746-A7FAEC1F-8F5E-408A-AA8A-5F006C49D1EE Q26752511-3EA22308-1B56-408E-B94A-E758B6CE3B7D Q26778095-DDECCF9D-7848-412E-A4BE-71DED7027B8F Q28068120-3900FA92-FB64-4A7B-9875-8DBF46024854 Q33660008-CEBF78BB-E229-4B07-8087-5CB9F6316030 Q34994502-0F4AA870-0C20-4B4C-8611-074B506BD9F1 Q35047406-A428C849-61E8-4B27-901D-B07A187F0D2C Q35438220-32BD8E40-CC37-4FF4-92EA-F981E3924057 Q35589875-BFE99BD6-B9B8-4949-924D-15798880F436 Q35769564-3D8A5674-4E1D-4089-811B-89E9E0115BF3 Q35973905-E81556E6-5C35-41BE-877D-3F200A54D1C2 Q36257733-1D06834C-22A0-46AF-B994-484E256F0EB5 Q36950218-08E8D163-54A0-40FF-8955-F9EF86C465AA Q38460480-C54660CE-02A3-44D3-B80E-7F6A1B6B107D Q38974881-F256EB2A-311A-4DF7-938F-320FE4FF59EA Q39132882-FFCDB6C6-86CB-4FC2-A606-6AA8500508B2 Q39331294-FC005D89-AB94-42D1-846F-DA817CE3E449 Q42145401-2570D04E-5C50-4A58-8844-873D21C6B4EE Q44877422-52B90C65-4F1A-4D13-9AC0-3E42BAC6DD32 Q46515365-F4F8DD48-2110-450D-B123-C179C782AA76 Q46564566-C97B5D07-C1F4-46F0-9867-94CF39DF9723 Q46624099-04898839-CED4-4926-95FF-94914821FE64 Q47119800-DC8BAD3A-CFD3-4523-8D3B-D96C5FA35808 Q48292012-CF25447A-D4B4-4CD8-B7F0-72DA072F8823 Q48329387-6A442C08-77AC-4594-8125-FB57A32CCB34 Q50205101-93AE24B6-B933-4039-85EC-DAB3F5C59C54 Q51484663-B11DD923-F017-45DB-90EC-2661051DEB3C Q55001495-05A27227-4B7C-4D4C-B235-6409E21F7592

P2860

Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism

http://www.wikidata.org/entity/Q35169945

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@ast

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@en

type

label

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@ast

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@en

prefLabel

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@ast

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@en

P1433

Q35169945-D8333EBA-BD6F-4D3C-8A99-7F7E4E3434E7

P1476

Q35169945-4F319A2B-FABE-491D-8092-D456B6166D93

P2093

Q35169945-05CA04B7-4EB0-4628-A3BB-C68CD3A41AF5

Q35169945-14276B05-E003-4BC3-92B8-1CBB2B0331FE

Q35169945-63E33E60-4EE4-4E47-BE74-1AE0438D7990

Q35169945-A4D3CD34-C87F-4D86-9A27-09E96CD80A2F

P2860

Q35169945-06990CF1-4FFD-49E9-BC97-E5F9DD786A08

Q35169945-16E767EC-0385-4E64-9F04-DE0E651E507D

Q35169945-1955B6D8-9FBE-4467-AE78-DC5C12EA6507

Q35169945-21C0F7DA-5CBF-4D8F-AAA7-DD342BD9D041

Q35169945-23CAEE03-A941-4171-AC8C-5ECABD1A9531

Q35169945-25C15FC2-744A-42FD-B29A-209B4C4611E3

Q35169945-25F3009E-8C09-4906-8CCA-3E7BDE2BB655

Q35169945-28FCB458-0619-436E-9F28-052D5C98F5CC

Q35169945-382FD2C3-8B4E-4980-A71F-127D1A133956

Q35169945-385E33E1-639C-42BE-9C3E-16DC54818406

P304

Q35169945-5C541E2D-180C-4D88-90A4-6FE1D0539AB8

P31

Q35169945-FECA5D2E-9A71-4701-9CAB-15A619364B3B

P356

Q35169945-4593B978-4FA4-4525-B2D1-1C0EE8A7909D

P407

Q35169945-5DCC126C-38F9-457C-AD14-4E30BDA8D07E

P433

Q35169945-6A96B4A2-23B2-4EB3-BD50-3080958CD990

P478

Q35169945-CEE9BC8E-18B4-4B0B-8BAA-776E0D1DB3DC

P577

Q35169945-53A9979D-70D6-4EED-A30F-0BC0A1D087D7

P5875

Q35169945-D0DD50F2-13C7-4EB7-923B-3EC993428291

P698

Q35169945-34788B2B-0760-4CDF-9950-4470A2AE40D6

P921

Q35169945-7CBCE663-8A8A-456F-9F03-A41BD486E5FE

P932

Q35169945-8EEA56B1-3909-4DF0-9337-81D0E561A1BD

P356

JOURNAL.PONE.0097554

P1433

P1476

Glucagon-like peptide-1 (GLP-1 ...... m and AMPK dependent mechanism

@en

P2093

Jose M Cacicedo

http://www.w3.org/2001/XMLSchema#string

Nadia M Krasner

http://www.w3.org/2001/XMLSchema#string

Neil B Ruderman

http://www.w3.org/2001/XMLSchema#string

Yasuo Ido

http://www.w3.org/2001/XMLSchema#string

P2860

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulin-dependent protein kinase kinase beta

Progress and challenges in translating the biology of atherosclerosis

Vascular adhesion molecules in atherosclerosis.

Of microbes and meals: the health consequences of dietary endotoxemia.

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

P304

e97554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0097554

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262420822

http://www.w3.org/2001/XMLSchema#string

P698

24835252

http://www.w3.org/2001/XMLSchema#string

P921

P932

4023984

http://www.w3.org/2001/XMLSchema#string